Analyst: US vaccine order secures future cash flow for Bavarian

BARDA has utilized a contract option concerning freeze-dried smallpox vaccines developed by Bavarian, something Sydbank analyst Søren Løntoft Hansen sees as a positive signal for the biotech firm.

Photo: Philip Davali/Ekstra Bladet, Philip Davali

Bavarian Nordic has secured million-dollar incomes for the next few years, as the US Biomedical Advanced Research and Development Authority (BARDA) has utilized its contracted option on Bavarian’s freeze-dried smallpox vaccine, Jynneos.

Søren Løntoft Hansen, who is a senior analyst at Danish bank Sydbank, says this sends a positive signal.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs